8-K 1 v029511.htm Unassociated Document

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 15, 2005
 
 
DrugMax, Inc.
  
 
(Exact name of registrant as specified in its charter)
  

 
STATE OF NEVADA
 
1-15445
 
34-1755390 
(State or other jurisdiction of incorporation)
  
(Commission File Number)
  
(IRS Employer Identification No.)
     
312 Farmington Avenue
Farmington, CT 06032-1968
(Address of principal executive offices)

Registrant’s telephone number, including area code: (860) 676-1222
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
o 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
o 
Pre-commencement communications pursuant to Rule 13e-4(c)) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

Item 2.02  Results of Operations and Financial Condition.

On November 15, 2005, DrugMax, Inc. issued a press release announcing its financial results for the third quarter ended October 1, 2005 and its decision to discontinue its legacy wholesale distribution business. A copy of this press release is furnished as Exhibit 99.1 to this report and is incorporated into this form 8-K by reference. The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, and shall not be deemed incorporated by reference into any filing made under the Securities Act of 1933, except as expressly set forth by specific reference in such filing.
 
Item 9.01  Financial Statements and Exhibits.

99.1        Press Release dated November 15, 2005

2


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

     
  DRUGMAX, INC.
 
 		  
 		  
 
  By:    /s/Edgardo A. Mercadante 
 
Edgardo A. Mercadante, President, Chief Executive
  Officer and Chairman of the Board
   
Dated: November 15, 2005  

3


EXHIBIT INDEX
 
Exhibit      
Number    Exhibit Description  
       
99.1   Press Release dated November 15, 2005  

4